Rejected at 11:13 p.m. Oct, 31, 2023 ] by dollajas
Author: shmuelsash
Related Note: 1472091045601 1
Rationale for change

Question 3990.21 from RX Bricks says it primarily affects phase 3

Rejection reason

this change would be better as an extra field change. would like to see a source from amboss or uworld supporting before approving this

Text Text
Extra
Prolongs the action potential and effective refractory period
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid

Sketchy



Watch Class III Antiarrhythmics
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize


Watch Dofetilide & Ibutilide


Watch Sotalol


Review Amiodarone



Physeo


Bootcamp
Watch associated Bootcamp video - Antiarrhythmics : Class III Antiarrhythmics
OME

Additional Resources
Empty field
One by one
Empty field
#AK_Step2_v12::#B&B::02_Cardio::05_Pharm::01_Cardiovascular_Pharmacology_I #AK_Step1_v12::#AMBOSS::d0aoUQ !AK_UpdateTags::Step1decks::Zanki-Pharmacology #AK_Step1_v12::#Pixorize::03_Pharmacology::21_Antiarrhythmics_(New)::07_Class_III_Sotalol #AK_Step1_v12::#AMBOSS::g5aFjO #AK_Step1_v12::#UWorld::Step::1507 #AK_Step1_v12::#Pixorize::03_Pharmacology::06_Cardiovascular_Pharm::13_Class_III_Antiarrhythmics-Ibutilide #AK_Step1_v12::#Pixorize::03_Pharmacology::21_Antiarrhythmics_(New)::08_Class_III_Amiodarone #AK_Step1_v12::#UWorld::COMLEX::24013 #AK_Step1_v12::^Other::^HighYield::2-RelativelyHighYield #AK_Step1_v12::#SketchyPharm::02_Cardio_&_Renal::04_Antiarrhythmics::03_Class_III #AK_Step1_v12::#Physeo::09_Pharm::10_Cardiac::19_Class_III_Antiarrhythmics #AK_Step1_v12::#Pixorize::03_Pharmacology::06_Cardiovascular_Pharm::11_Class_III_Antiarrhythmics-Amiodarone #AK_Step1_v12::#UWorld::COMLEX::24618 #PANCE::EOR::Family_med #AK_Step1_v12::#B&B::05_Cardio::04_Arrhythmias::06_Antiarrhythmic_Drugs_I #PANCE::CARDIO::conduction_disorders/dysrhythmias #AK_Step1_v12::#FirstAid::07_Cardiovascular::05_Pharm::12_Antiarrhythmics-sodium_channel_blockers_(class_I)::*16_Antiarrythmics::Class_3_Potassium_Channel_Blockers #AK_Step1_v12::#OME::04_Organ_Systems::01_Cardiology::04_Electricity::05_Anti-Arrhythmics #AK_Step1_v12::#AMBOSS::0MaeMO #PANCE::EOR::IM #AK_Step1_v12::#AMBOSS::Nca-cj #AK_Step1_v12::#OME::Clinical::04_Organ_Systems::01_Cardiology::04_Electricity::05_Anti-Arrhythmics #AK_Step1_v12::#Pixorize::03_Pharmacology::21_Antiarrhythmics_(New)::02_Dofetilide_&_Ibutilide #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::^Systems::Cardio::Pharmacology #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Pixorize::03_Pharmacology::06_Cardiovascular_Pharm::12_Class_III_Antiarrythmics-Sotalol #AK_Step1_v12::#UWorld::Step::901 #AK_Step1_v12::#Bootcamp::Cardiology::13_Antiarrhythmics::04_Class_III_Antiarrhythmics